Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis
Open accessThe DOI matches its OpenAlex record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis is a progressive and fatal fibrotic disease of the lungs with unclear etiology. Prior efforts to treat idiopathic pulmonary fibrosis that focused on anti-inflammatory therapy have not proven to be effective. Recent insight suggests that the pathogenesis is mediated through foci of dysregulated fibroblasts driven by profibrotic cytokine signaling. TGF-beta and PDGF are 2 of the most potent of these cytokines. In the current study, we investigated the role of TGF-beta-induced fibrosis mediated by activation of the Abelson (Abl) tyrosine kinase. Our data indicate that fibroblasts respond to TGF-beta by stimulating c-Abl kinase activity independently of Smad2/3 phosphorylation or PDGFR activation. Moreover, inhibition of c-Abl by imatinib prevented TGF-beta-induced ECM gene expression, morphologic transformation, and cell proliferation independently of any effect on Smad signaling. Further, using a mouse model of bleomycin-induced pulmonary fibrosis, we found a significant inhibition of lung fibrosis by imatinib. Thus, Abl family members represent common targets for the modulation of profibrotic cytokine signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transforming Growth Factor β in Tissue Fibrosis
Epstein, F. H., Border, W. A., & Noble, N. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311907 · Cited by 3,069
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Role of Transforming Growth Factor β in Human Disease
Blobe, G. C., Schiemann, W. P., & Lodish, H. F. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005043421807 · Cited by 2,427
Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Sime, P. J., Xing, Z., Graham, F. L., Csaky, K. G., & Gauldie, J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119590 · Cited by 1,050
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039 · cited 2×
“progressive clinical course with median survival less than 3 years from diagnosis (3).”
BackgroundKaartinen, V., Voncken, J. W., Shuler, C., Warburton, D., Bu, D., Heisterkamp, N., & Groffen, J. (1995) · Nature Genetics · doi:10.1038/ng1295-415 · Cited by 1,031
The epidemiology of interstitial lung diseases.
Coultas, D. B., Zumwalt, R. E., Black, W. C., & Sobonya, R. E. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.150.4.7921471 · Cited by 946
international consensus statement
Clements, R. V., & Simanowitz, A. (2000) · Cited by 852
Research works printed but not linked: 8
- Cohen, 2002, Clin. Cancer Res., 8, 935
- Salgia, 1999, Blood., 94, 4233
- Andrews, 1999, Invest. Ophthalmol. Vis. Sci., 40, 2683
- 10.1074/jbc.M000711200 · doi:10.1074/jbc.m000711200
- Hu, 2003, Am. J. Respir. Crit. Care Med., 29, 397
- Butt, 1995, Eur. J. Cell Biol., 68, 330
- Adamson, 1974, Am. J. Pathol., 77, 185
- Cutroneo, 1986, Chest., 89(3 Suppl.), 121S, 10.1378/chest.89.3_Supplement.121S · doi:10.1378/chest.89.3_supplement.121s
Cited by
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
Non-Smad pathways in TGF-β signaling
Zhang, Y. E. (2009) · Cell Research · doi:10.1038/cr.2008.328 · Cited by 1,749
Transforming growth factor–β in tissue fibrosis
Frangogiannis, N. G. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190103 · Cited by 1,278
Systemic sclerosis: a prototypic multisystem fibrotic disorder
Varga, J., & Abraham, D. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31139 · Cited by 1,163
Biernacka, A., Dobaczewski, M., & Frangogiannis, N. G. (2011) · Growth Factors · doi:10.3109/08977194.2011.595714 · Cited by 1,161
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Kerkelä, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, S., Pesant, S., Clubb, F. J., et al. (2006) · Nature Medicine · doi:10.1038/nm1446 · Cited by 1,159
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1328 · Cited by 1,034
Moeller, A., Ask, K., Warburton, D., Gauldie, J., & Kolb, M. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.08.011 · Cited by 1,007
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005
Moustakas, A., & Heldin, C.-H. (2005) · Journal of Cell Science · doi:10.1242/jcs.02554 · Cited by 958
Transforming growth factor (TGF)-β signaling in cardiac remodeling
Dobaczewski, M., Chen, W., & Frangogiannis, N. G. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.10.033 · Cited by 934
The role of TGF-β signaling in myocardial infarction and cardiac remodeling
BUJAK, M., & FRANGOGIANNIS, N. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.10.002 · Cited by 927
Tzavlaki, K., & Moustakas, A. (2020) · Biomolecules · doi:10.3390/biom10030487 · Cited by 796
Specificity, versatility, and control of TGF-β family signaling
Derynck, R., & Budi, E. H. (2019) · Science Signaling · doi:10.1126/scisignal.aav5183 · Cited by 785
Non-Smad Signaling Pathways of the TGF-β Family
Zhang, Y. E. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022129 · Cited by 697
Acellular Normal and Fibrotic Human Lung Matrices as a Culture System for In Vitro Investigation
Booth, A. J., Hadley, R., Cornett, A. M., Dreffs, A. A., Matthes, S. A., Tsui, J. L., Weiss, K., Horowitz, J. C., Fiore, V. F., Barker, T. H., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0754oc · Cited by 665
“As proof of this shortcoming, many therapeutic agents that are shown to be successful in bleomycin-induced lung fibrosis are often ineffective in patients with IPF (50, 51).”
BackgroundThe immune system and cardiac repair
FRANGOGIANNIS, N. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.06.007 · Cited by 641
TGF-β and fibrosis in different organs — molecular pathway imprints
Pohlers, D., Brenmoehl, J., Löffler, I., Müller, C. K., Leipner, C., Schultze-Mosgau, S., Stallmach, A., Kinne, R. W., & Wolf, G. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.06.004 · Cited by 576
Molecular Targets in Pulmonary Fibrosis
Scotton, C. J., & Chambers, R. C. (2007) · Chest · doi:10.1378/chest.06-2568 · Cited by 538
Targeting metabolic dysregulation for fibrosis therapy
Zhao, X., Kwan, J. Y. Y., Yip, K., Liu, P. P., & Liu, F.-F. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0040-5 · Cited by 513
Li, D., Guabiraba, R., Besnard, A.-G., Komai-Koma, M., Jabir, M. S., Zhang, L., Graham, G. J., Kurowska-Stolarska, M., Liew, F. Y., McSharry, C., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.05.011 · Cited by 413
Meltzer, E. B., & Noble, P. W. (2008) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-3-8 · Cited by 407
Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis
Abdollahi, A., Li, M., Ping, G., Plathow, C., Domhan, S., Kiessling, F., Lee, L. B., McMahon, G., Gröne, H.-J., Lipson, K. E., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041393 · Cited by 388
Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis
Chaudhary, N. I., Roth, G. J., Hilberg, F., Müller-Quernheim, J., Prasse, A., Zissel, G., Schnapp, A., & Park, J. E. (2007) · European Respiratory Journal · doi:10.1183/09031936.00152106 · Cited by 386
Distler, J. H. W., Jüngel, A., Huber, L. C., Schulze‐Horsel, U., Zwerina, J., Gay, R. E., Michel, B. A., Hauser, T., Schett, G., Gay, S., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22314 · Cited by 383
Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities
Bhattacharyya, S., Wei, J., & Varga, J. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.149 · Cited by 381
“c-Abl mediates fibrotic responses In normal fibroblasts, but not epithelial cells, both TGF-β and PDGF activate c-Abl, a non-receptor tyrosine kinase associated with chronic myelogenous leukemia (CML)”
Mitochondrial Reactive Oxygen Species Regulate Transforming Growth Factor-β Signaling
Jain, M., Rivera, S., Monclus, E. A., Synenki, L., Zirk, A., Eisenbart, J., Feghali-Bostwick, C., Mutlu, G. M., Budinger, G. R. S., & Chandel, N. S. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.431973 · Cited by 381
Imatinib Treatment for Idiopathic Pulmonary Fibrosis: Randomized Placebo-controlled Trial Results
Daniels, C. E., Lasky, J. A., Limper, A. H., Mieras, K., Gabor, E., & Schroeder, D. R. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0964oc · Cited by 373
Self-citationTGF‐β signaling: A tale of two responses
Rahimi, R. A., & Leof, E. B. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21501 · Cited by 371
Self-citationChakraborty, D., Šumová, B., Mallano, T., Chen, C.-W., Distler, A., Bergmann, C., Ludolph, I., Horch, R. E., Gelse, K., Ramming, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01236-6 · Cited by 356
Pharmacologic Differentiation of Inflammation and Fibrosis in the Rat Bleomycin Model
Chaudhary, N. I., Schnapp, A., & Park, J. E. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200505-717oc · Cited by 358
TGF-β in Renal Injury and Disease
Böttinger, E. P. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.02.009 · Cited by 339
Biology of Platelet-Derived Growth Factor and Its Involvement in Disease
Alvarez, R. H., Kantarjian, H. M., & Cortes, J. E. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.9.1241 · Cited by 334
Varga, J., Trojanowska, M., & Kuwana, M. (2017) · Journal of Scleroderma and Related Disorders · doi:10.5301/jsrd.5000249 · Cited by 323
Transforming growth factor β as a therapeutic target in systemic sclerosis
Varga, J., & Pasche, B. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.26 · Cited by 295
Mouse models of graft-versus-host disease: advances and limitations
Schroeder, M. A., & DiPersio, J. F. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.006668 · Cited by 291
Fibrosis of two: Epithelial cell-fibroblast interactions in pulmonary fibrosis
Sakai, & Tager, A. M. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.03.001 · Cited by 285
Day, E., Waters, B., Spiegel, K., Alnadaf, T., Manley, P. W., Buchdunger, E., Walker, C., & Jarai, G. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.10.014 · Cited by 277
Pulmonary hypertension in interstitial lung disease: Fig. 1—
Behr, J., & Ryu, J. H. (2008) · European Respiratory Journal · doi:10.1183/09031936.00171307 · Cited by 263
Spagnolo, P., Distler, O., Ryerson, C. J., Tzouvelekis, A., Lee, J. S., Bonella, F., Bouros, D., Hoffmann-Vold, A.-M., Crestani, B., & Matteson, E. L. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217230 · Cited by 259
Hostettler, K. E., Zhong, J., Papakonstantinou, E., Karakiulakis, G., Tamm, M., Seidel, P., Sun, Q., Mandal, J., Lardinois, D., Lambers, C., et al. (2014) · Respiratory Research · doi:10.1186/s12931-014-0157-3 · Cited by 258
TGF-β and Smad3 Signaling Link Inflammation to Chronic Fibrogenesis
Bonniaud, P., Margetts, P. J., Ask, K., Flanders, K., Gauldie, J., & Kolb, M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.8.5390 · Cited by 252
“Likewise, if the platelet-derived growth factor receptor tyrosine kinase is blocked by imatinib, there is no alteration in the inflammation, but a marked reduction in bleomycin fibrosis (19, 20), suggesting the Abl pathway from the TGF- R may also be involved in fibrogenesis.”
BackgroundAkhmetshina, A., Dees, C., Pileckyte, M., Maurer, B., Axmann, R., Jüngel, A., Zwerina, J., Gay, S., Schett, G., Distler, O., et al. (2008) · The FASEB Journal · doi:10.1096/fj.07-105627 · Cited by 187
Spiera, R. F., Gordon, J. K., Mersten, J. N., Magro, C. M., Mehta, M., Wildman, H. F., Kloiber, S., Kirou, K. A., Lyman, S., & Crow, M. K. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.143974 · Cited by 173
Transforming Growth Factor- β Activation in the Lung: Focus on Fibrosis and Reactive Oxygen Species
Koli, K., Myllärniemi, M., Keski-Oja, J., & Kinnula, V. L. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1914 · Cited by 168
Liu, Y., Wang, Z., Kwong, S. Q., Lui, E. L. H., Friedman, S. L., Li, F. R., Lam, R. W. C., Zhang, G. C., Zhang, H., & Ye, T. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.11.035 · Cited by 168
“The importance of Abl for the production of ECM is underscored by the finding that the induction of ECM by TGFb is strongly reduced in cells lacking Abl, and inhibitors of Abl reduce collagen production [37].”
BackgroundUnraveling SSc Pathophysiology; The Myofibroblast
van Caam, A., Vonk, M., van den Hoogen, F., van Lent, P., & van der Kraan, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02452 · Cited by 153
Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years
Raghu, G. (2017) · European Respiratory Journal · doi:10.1183/13993003.01209-2017 · Cited by 146
Platelet-derived growth factor-producing CD4+ Foxp3+ regulatory T lymphocytes promote lung fibrosis
Lo Re, S., Lecocq, M., Uwambayinema, F., Yakoub, Y., Delos, M., Demoulin, J.-B., Lucas, S., Sparwasser, T., Renauld, J.-C., Lison, D., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201103-0516oc · Cited by 128
“Although PDGF induces fibroblast recruitment and proliferation (39), TGF-b stimulates extracellular matrix synthesis and fibroblast morphologic transformation (40).”
Fraticelli, P., Gabrielli, B., Pomponio, G., Valentini, G., Bosello, S., Riboldi, P., Gerosa, M., Faggioli, P., Giacomelli, R., Del Papa, N., et al. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4606 · Cited by 108
“Interest in use of imatinib mesylate in SSc lies in its ability to interfere with the tyrosine kinases downstream of the receptors for transforming growth factor beta and platelet-derived growth factor, which are considered key signaling molecules in the pathogenesis of SSc fibrosis [8,9].”
BackgroundMartyanov, V., Kim, G.-H. J., Hayes, W., Du, S., Ganguly, B. J., Sy, O., Lee, S. K., Bogatkevich, G. S., Schieven, G. L., Schiopu, E., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0187580 · Cited by 71
Mazhari, S., Gitiara, A., Baghaei, K., Hatami, B., Rad, R. E., Asadirad, A., Joharchi, K., Tokhanbigli, S., Hashemi, S. M., Łos, M. J., et al. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173263 · Cited by 22
Karimizadeh, E., Gharibdoost, F., Motamed, N., Jafarinejad-Farsangi, S., Jamshidi, A., & Mahmoudi, M. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2408-0 · Cited by 20
Wu, X., Li, W., Luo, Z., & Chen, Y. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-02861-w · Cited by 9
Metadata
- Authors
- Daniels, C. E., Wilkes, M. C., Edens, M., Kottom, T. J., Murphy, S. J., LIMPER, A. H., & Leof, E. B.
- Venue
- Journal of Clinical Investigation
- Published
- 2004-11-01
- Volume
- 114
- Issue
- 9
- Pages
- 1308-1316
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1977445008
- Cited by
- 574
- References
- 53
- FWCI
- 23.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.